Journal: Frontiers in Veterinary Science

Article Title: Unrevealing the therapeutic potential of artesunate against emerging zoonotic Babesia microti infection in the murine model

doi: 10.3389/fvets.2024.1383291

Figure Lengend Snippet: Regulating effect of artesunate (AS) after 4 weeks of treatment. (A) Shows protein levels of inflammation markers including SICAM-1, ICAM-1, and C-reactive protein and proapoptotic factor Bax and anti-apoptotic factor Bcl-2. (B) Shows a bar graph of the percentage of band intensity relative protein expression compared within the control group (CG), the B. microti (BM) group, and the experimental groups B. microti + artesunate 2 mg/kg low-dose group (LG), B . microti + artesunate 4 mg/kg medium-dose group, and 8 mg/kg high-dose group. (a) SICAM-1, (b) ICAM-1, (c) CRP, (d) BAX, (e) Bcl-2 bar graph, with asterisks representing a higher level of significance, “*” ( p < 0.05) “**”( p < 0.01) ***”( p < 0.001)”****”( p < 0.0001).

Article Snippet: 3 , ICAM-1 , ICAM-1; 1:2000; Catalogue# HY-P80502; Med Chem Express, China.

Techniques: Expressing, Control

Journal: Annals of Translational Medicine

Article Title: The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

doi: 10.21037/atm-21-1854

Figure Lengend Snippet: The primers of RT-PCR assays

Article Snippet: The primary antibodies used for the western blot were MMP9 (BOSTER, PB9669; 1:1,000), JUN (BOSTER, BM4168; 1:1,000), ICAM1 (BOSTER, PB9018; 1:1,000), VCAM1 (BOSTER, A01199; 1:1,000) and GAPDH (Cell Signaling Technology, 5174; 1:40,000).

Techniques:

Journal: Annals of Translational Medicine

Article Title: The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

doi: 10.21037/atm-21-1854

Figure Lengend Snippet: Top 10 nodes in the network ranked by degree

Article Snippet: The primary antibodies used for the western blot were MMP9 (BOSTER, PB9669; 1:1,000), JUN (BOSTER, BM4168; 1:1,000), ICAM1 (BOSTER, PB9018; 1:1,000), VCAM1 (BOSTER, A01199; 1:1,000) and GAPDH (Cell Signaling Technology, 5174; 1:40,000).

Techniques:

Journal: Annals of Translational Medicine

Article Title: The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

doi: 10.21037/atm-21-1854

Figure Lengend Snippet: Molecular docking scores of celastrol with the target proteins (kcal/mol)

Article Snippet: The primary antibodies used for the western blot were MMP9 (BOSTER, PB9669; 1:1,000), JUN (BOSTER, BM4168; 1:1,000), ICAM1 (BOSTER, PB9018; 1:1,000), VCAM1 (BOSTER, A01199; 1:1,000) and GAPDH (Cell Signaling Technology, 5174; 1:40,000).

Techniques:

Journal: Annals of Translational Medicine

Article Title: The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

doi: 10.21037/atm-21-1854

Figure Lengend Snippet: Molecular docking data indicated that the binding capacity of celastrol with PTC was significant in the key targets of MMP9 (A), JUN (B), ICAM1 (C), and VCAM1 (D). PTC, papillary thyroid carcinoma.

Article Snippet: The primary antibodies used for the western blot were MMP9 (BOSTER, PB9669; 1:1,000), JUN (BOSTER, BM4168; 1:1,000), ICAM1 (BOSTER, PB9018; 1:1,000), VCAM1 (BOSTER, A01199; 1:1,000) and GAPDH (Cell Signaling Technology, 5174; 1:40,000).

Techniques: Binding Assay

Journal: Annals of Translational Medicine

Article Title: The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

doi: 10.21037/atm-21-1854

Figure Lengend Snippet: The differentially expressed of four core proteins in BCPAP cell line after 24 hrs of celastrol treatment. (A) qRT-PCR was used to detect the MMP9, JUN, ICAM1, VCAM1 expression with or without celastrol treatment. (B) Western blotting analyses of MMP9, JUN, ICAM1, VCAM1 expression with or without celastrol treatment. **, P<0.01; ***, P<0.001. Data are expressed as means ± SD.

Article Snippet: The primary antibodies used for the western blot were MMP9 (BOSTER, PB9669; 1:1,000), JUN (BOSTER, BM4168; 1:1,000), ICAM1 (BOSTER, PB9018; 1:1,000), VCAM1 (BOSTER, A01199; 1:1,000) and GAPDH (Cell Signaling Technology, 5174; 1:40,000).

Techniques: Quantitative RT-PCR, Expressing, Western Blot

Journal: Genetics and molecular research : GMR

Article Title: Active vitamin D3, 1,25-(OH)2D3, protects against macrovasculopathy in a rat model of type 2 diabetes mellitus.

doi: 10.4238/gmr.15028113

Figure Lengend Snippet: Figure 5. CD54 expression in the thoracic aorta of rats in (A) control group, (B) T2DM (type 2 diabetes mellitus) group, and (C) treatment group. (Immunohistological staining, 400X).

Article Snippet: Streptozotocin (Sigma-Aldrich, USA), calcitriol (Roche, Shanghai, China), monoclonal antibodies against TNF-α, ET, eNOS, CD54, and CD106 (Boster, Wuhan, China), PV-9000 Polymer Detection System for Immuno-Histological Staining, DAB kit (ZSGB-Bio, Beijing, China), and full-automatic biochemical analyzer (ABX, France) were used in this experiment.

Techniques: Expressing, Control, Staining